# Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

> **NCT03023722** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 18 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** anetumab ravtansine

## Key facts

- **NCT ID:** NCT03023722
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-11
- **Primary completion:** 2019-08-06
- **Final completion:** 2019-12-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03023722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03023722, "Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03023722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*